Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Clinical trial design in systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Curr Opin Rheumatol. 2006 Sep;18(5):476-80. Review.

PMID:
16896285
2.
3.
4.

Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus.

Karassa FB, Tatsioni A, Ioannidis JP.

J Rheumatol. 2003 May;30(5):979-84.

PMID:
12734892
5.

Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.

Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA, Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F.

J Rheumatol. 1999 Feb;26(2):504-7.

PMID:
9972996
6.

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.

Gordon C, Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostál C, Font J, Gilboe IM, Houssiau F, Huizinga TW, Isenberg D, Kallenberg CG, Khamashta MA, Piette JC, Schneider M, Smolen JS, Sturfelt G, Tincani A, Van Vollenhoven R, Boumpas DT.

Ann Rheum Dis. 2009 Apr;68(4):470-6. doi: 10.1136/ard.2007.083022. Epub 2008 Apr 3. Review.

PMID:
18388158
7.

Measuring outcomes in systemic lupus erythematosus clinical trials.

Strand V, Chu AD.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):455-68. doi: 10.1586/erp.11.38. Review.

PMID:
21831027
8.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
9.

Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.

Yuen SY, Pope JE.

Rheumatology (Oxford). 2008 Sep;47(9):1367-72. doi: 10.1093/rheumatology/ken230. Epub 2008 Jun 24. Review.

11.
12.

Immunotherapy of systemic lupus erythematosus.

O'Neill SG, Schrieber L.

Autoimmun Rev. 2005 Jul;4(6):395-402. Epub 2005 Apr 19. Review.

PMID:
16081031
13.

Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.

Murdaca G, Colombo BM, Puppo F.

Autoimmun Rev. 2011 Nov;11(1):56-60. doi: 10.1016/j.autrev.2011.07.006. Epub 2011 Jul 30. Review.

PMID:
21835271
14.

Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study.

Costenbader KH, Brome D, Blanch D, Gall V, Karlson E, Liang MH.

Arthritis Rheum. 2007 Feb 15;57(1):49-55.

15.

Re-evaluation of biologic therapies in systemic lupus erythematosus.

Bruce IN.

Curr Opin Rheumatol. 2010 May;22(3):273-7. doi: 10.1097/BOR.0b013e3283374e78. Review.

PMID:
20177385
16.

Target therapies in systemic lupus erythematosus: current state of the art.

Wiesik-Szewczyk E, Lacki JK, Feleszko W, Olesinska M.

Mini Rev Med Chem. 2010 Sep;10(10):956-65. Review.

PMID:
21034417
17.

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints.

Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Boumpas DT, Gordon C.

Ann Rheum Dis. 2009 Apr;68(4):477-83. doi: 10.1136/ard.2007.083030. Epub 2008 Apr 23. Review.

PMID:
18434449
18.

Evaluation of recent clinical trials in lupus.

Brooks EB, Liang MH.

Curr Opin Rheumatol. 1999 Sep;11(5):341-7. Review.

PMID:
10503652
19.

Biologics in the treatment of systemic lupus erythematosus.

Lateef A, Petri M.

Curr Opin Rheumatol. 2010 Sep;22(5):504-9. doi: 10.1097/BOR.0b013e32833b475e. Review.

PMID:
20502332
20.

Endpoints for randomised controlled trials in systemic lupus erythematosus.

Aringer M, Strand V.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):147-51. Epub 2012 Apr 13. No abstract available.

PMID:
22546067
Items per page

Supplemental Content

Write to the Help Desk